The centre for cancer therapeutics at the Institute of Cancer Research has chosen ActivityBase as the data management platform for its drug discovery operations
The need for direct access to a comprehensive drug discovery data resource for the academics, clinicians, and management at the centre for cancer therapeutics at the Institute of Cancer Research, as well as its many collaboration partners, was a key factor in the selection of ActivityBase from IDBS.
The Institute is part of the University of London and, together with its hospital partner the Royal Marsden NHS Foundation Trust, forms the largest cancer centre in Europe.
An academic institution significantly funded by charitable donations, the Institute of Cancer Research operates a full-scale drug discovery programme at the forefront of world-class cancer research.
ActivityBase will underpin the discovery operations at the Institute's centre for cancer therapeutics, encompassing basic research, biology, chemistry, high throughput screening and pharmacology.
Professor Paul Workman, centre director, commented: "We are pleased to be working with ActivityBase to help accelerate our search for new drugs that are designed to act on new molecular targets responsible for various cancers.
"The objective is to get these treatments to our cancer patients as rapidly as possible".
Commenting on the reasons for selecting ActivityBase, Wynne Aherne, compound screening team leader at the centre, said: "We sought an adaptable informatics system to integrate all our compound information including Adme, pharmacokinetics and mass spectrometry data as well as primary and secondary screening results".
Dr Aherne continued, "We have many collaborators in the pharmaceutical, biotechnology and academic sectors and need to share data with them in a straightforward and professional manner.
"Our evaluation of ActivityBase has shown that the software will help us achieve all of these goals".
"Communication between scientists - both within organisations and between discovery partners - is one of the keys to success in drug research," commented Neil Kipling, chairman and CEO of IDBS.
"The Institute of Cancer Research is one of the world's leading research institutions and we are delighted that ActivityBase will facilitate the sharing of information between the Institute and its collaborators in order to accelerate progress in the fight against cancer."
